Barclays Boosts Replimune Group (NASDAQ:REPL) Price Target to $50.00
Replimune Group (NASDAQ:REPL) had its price objective raised by Barclays from $29.00 to $50.00 in a research note published on Thursday morning, The Fly reports. The brokerage currently has an overweight rating on the stock.
Other equities analysts have also issued reports about the company. Roth Capital increased their price objective on Replimune Group from $30.00 to $50.00 and gave the stock a buy rating in a report on Wednesday. Chardan Capital increased their price target on Replimune Group from $30.00 to $48.00 and gave the company a buy rating in a research note on Wednesday. BidaskClub raised Replimune Group from a sell rating to a hold rating in a research note on Tuesday, September 1st. Zacks Investment Research raised Replimune Group from a sell rating to a hold rating in a research note on Saturday, October 10th. Finally, HC Wainwright raised Replimune Group from a neutral rating to a buy rating and increased their price target for the company from $25.00 to $54.00 in a research note on Thursday. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Replimune Group presently has a consensus rating of Buy and a consensus target price of $42.06.
Shares of REPL stock opened at $40.98 on Thursday. Replimune Group has a 12-month low of $8.58 and a 12-month high of $46.30. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -24.69 and a beta of 3.20. The business has a 50 day simple moving average of $24.54 and a 200 day simple moving average of $20.54. The company has a debt-to-equity ratio of 0.14, a current ratio of 22.54 and a quick ratio of 22.54.
In other news, COO Colin Love sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $23.44, for a total transaction of $351,600.00. Following the completion of the sale, the chief operating officer now directly owns 1,042,488 shares of the company’s stock, valued at approximately $24,435,918.72. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Pamela Esposito sold 16,000 shares of the firm’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $32.90, for a total value of $526,400.00. Following the sale, the insider now directly owns 128,700 shares of the company’s stock, valued at $4,234,230. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,000 shares of company stock valued at $1,013,250. Corporate insiders own 50.90% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nuveen Asset Management LLC lifted its holdings in shares of Replimune Group by 267.0% in the first quarter. Nuveen Asset Management LLC now owns 165,521 shares of the company’s stock valued at $1,650,000 after purchasing an additional 120,425 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Replimune Group by 119.0% in the first quarter. BNP Paribas Arbitrage SA now owns 4,071 shares of the company’s stock valued at $41,000 after purchasing an additional 2,212 shares in the last quarter. Great West Life Assurance Co. Can purchased a new stake in shares of Replimune Group in the second quarter valued at $42,000. FMR LLC lifted its holdings in shares of Replimune Group by 26.7% in the second quarter. FMR LLC now owns 1,127,619 shares of the company’s stock valued at $28,021,000 after purchasing an additional 237,859 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in shares of Replimune Group by 150.0% in the second quarter. Victory Capital Management Inc. now owns 1,121,009 shares of the company’s stock valued at $27,857,000 after purchasing an additional 672,623 shares in the last quarter. 60.86% of the stock is owned by institutional investors and hedge funds.
Replimune Group Company Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Further Reading: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.